• LAST PRICE
    43.0500
  • TODAY'S CHANGE (%)
    Trending Up0.0500 (0.1163%)
  • Bid / Lots
    35.0000/ 1
  • Ask / Lots
    55.0000/ 1
  • Open / Previous Close
    42.8800 / 43.0000
  • Day Range
    Low 42.3750
    High 43.5450
  • 52 Week Range
    Low 27.9850
    High 50.9900
  • Volume
    364,266
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 43
TimeVolumeXENE
09:32 ET209542.88
09:34 ET61542.55
09:36 ET20042.86
09:38 ET10042.645
09:39 ET20042.485
09:45 ET10042.62
09:50 ET40042.65
09:52 ET40042.705
09:54 ET10042.75
09:56 ET40042.595
09:57 ET10042.53
10:01 ET80042.58
10:03 ET160042.625
10:08 ET230642.61
10:10 ET10042.61
10:12 ET10042.61
10:14 ET34342.62
10:24 ET20042.75
10:28 ET30042.755
10:33 ET20042.72
10:35 ET70442.79
10:37 ET10042.78
10:39 ET10042.79
10:42 ET30042.79
10:46 ET30042.82
10:50 ET10042.8
10:51 ET140242.955
10:53 ET455742.89
10:55 ET10042.92
11:00 ET40042.92
11:02 ET297642.84
11:04 ET100042.9
11:06 ET30042.885
11:08 ET20042.87
11:09 ET502342.97
11:11 ET10042.95
11:15 ET10042.975
11:29 ET10042.995
11:31 ET130042.99
11:33 ET10043.01
11:36 ET180042.58
11:38 ET120042.68
11:42 ET71542.76
11:51 ET10042.72
11:54 ET30042.795
11:58 ET30042.8
12:00 ET20042.8
12:02 ET70042.92
12:09 ET10042.9
12:12 ET30042.85
12:14 ET40042.895
12:18 ET798443.125
12:20 ET167643.1
12:32 ET73343.075
12:34 ET10043.05
12:36 ET50043.04
12:38 ET10043.015
12:43 ET60042.945
12:45 ET419043.02
12:48 ET68042.97
12:50 ET20042.96
12:52 ET10042.97
12:54 ET10442.96
12:56 ET20042.965
12:57 ET20042.95
01:01 ET32242.89
01:03 ET90542.92
01:06 ET10042.915
01:08 ET50042.96
01:14 ET20042.97
01:15 ET40042.985
01:19 ET10042.99
01:21 ET50142.95
01:24 ET180042.91
01:28 ET30042.96
01:30 ET40042.94
01:32 ET10042.86
01:39 ET50042.825
01:42 ET110042.78
01:44 ET70042.835
01:50 ET10042.845
01:51 ET62542.83
01:55 ET20042.83
01:57 ET104042.915
02:00 ET20042.96
02:02 ET180043.055
02:06 ET30043.04
02:08 ET168043.25
02:11 ET10043.31
02:15 ET30043.27
02:18 ET64843.24
02:20 ET54843.17
02:22 ET40043.185
02:24 ET27043.1574
02:26 ET100743.26
02:27 ET10043.22
02:29 ET10043.24
02:31 ET110043.32
02:33 ET30043.3
02:36 ET40043.37
02:38 ET918443.175
02:40 ET84843.14
02:42 ET10043.16
02:45 ET218043.14
02:47 ET10043.1
02:49 ET142243.17
02:51 ET63643.18
02:54 ET10043.15
02:56 ET30043.185
02:58 ET50043.195
03:00 ET44343.24
03:02 ET10043.215
03:05 ET30043.17
03:07 ET10043.13
03:09 ET20043.14
03:12 ET30043.145
03:18 ET210043.085
03:20 ET20043.05
03:21 ET80943.08
03:23 ET52543.05
03:25 ET33943.005
03:27 ET61043.04
03:30 ET24043
03:32 ET80042.995
03:34 ET240543.13
03:36 ET10043.145
03:41 ET20043.155
03:43 ET20043.155
03:45 ET361943.05
03:48 ET70042.93
03:50 ET197842.985
03:52 ET352943.1
03:54 ET417243.32
03:56 ET567343.08
03:57 ET750643.13
03:59 ET586443.05
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXENE
Xenon Pharmaceuticals Inc
3.2B
-15.8x
---
United StatesMLTX
MoonLake Immunotherapeutics
3.2B
-65.9x
---
United StatesIDYA
IDEAYA Biosciences Inc
3.2B
-22.4x
---
United StatesVSBC
Vitaspring Biomedical Co. Ltd
3.1B
3,311.3x
---
United StatesCRNX
Crinetics Pharmaceuticals Inc
3.5B
-12.7x
---
United StatesIBRX
Immunitybio Inc
3.7B
-4.8x
---
As of 2024-03-28

Company Information

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Contact Information

Headquarters
3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
Phone
604-484-3300
Fax
604-484-3450

Executives

Chairman of the Board
Simon Pimstone
President, Chief Executive Officer, Director
Ian Mortimer
Chief Financial Officer
Sherry Aulin
Executive Vice President - Drug Discovery
James Empfield
Executive Vice President - Strategy and Innovation
Robin Sherrington

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.2B
Revenue (TTM)
$0.00
Shares Outstanding
75.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.15
EPS
$-2.73
Book Value
$12.31
P/E Ratio
-15.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.